pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
REGN1193
Phase 1 · small molecule · Diabetes Mellitus, Type 2
REGN1193 for Diabetes Mellitus, Type 2 is a Phase 1 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Internal code R1193-DM-1402
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron UK Limited
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Diabetes Mellitus, Type 2
- Status
- terminated
- Trials
- 1